Adjuvant Therapy for EBC

CE / CME

Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: February 05, 2025

Expiration: August 04, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following could indicate high-risk disease and inform adjuvant therapy decision-making for a patient with newly diagnosed HR+/HER2- EBC?

2.

Case: 56 Yr-Old Female With HR+/HER2- Breast Cancer



  • 56-yr-old female presenting with a screen-detected mass in the right breast; diagnostic ultrasound reveals the mass to be 2.5 x 1.9 x 2.7 cm; MRI reveals extensive multicentric right breast enhancement spanning 12.3 x 6.4 x 10.1 cm with multilevel axillary adenopathy 

  • Biopsy of right breast and axilla, both positive for malignancy; invasive ductal carcinoma, grade II, ER 91%-100%, PR negative, HER-2 1+ 

  • PET revealed known malignancy in right breast and axilla with skin thickening; no distant disease noted

  • Germline genetics revealed CHEK2 mutation

  • Clinical stage: cT4dN3c

  • Patient received neoadjuvant chemotherapy, T-AC

  • Patient proceeded to bilateral mastectomy; right breast revealed 5 mm of residual invasive ductal carcinoma, grade II; 12 lymph nodes removed—1 with macrometastasis, 1 with micrometastasis, and 1 with ITC

What is your next step after seeing her for a postoperative discussion?